BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35730321)

  • 1. Effectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity.
    Kudo R; Sekine M; Yamaguchi M; Hara M; Hanley SJB; Kurosawa M; Adachi S; Ueda Y; Miyagi E; Ikeda S; Yagi A; Enomoto T
    Cancer Sci; 2022 Sep; 113(9):3211-3220. PubMed ID: 35730321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.
    Kurosawa M; Sekine M; Yamaguchi M; Kudo R; Hanley SJB; Hara M; Adachi S; Ueda Y; Miyagi E; Ikeda S; Yagi A; Enomoto T
    Cancer Sci; 2022 Apr; 113(4):1435-1440. PubMed ID: 35100477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.
    Onuki M; Yamamoto K; Yahata H; Kanao H; Yokota H; Kato H; Shimamoto K; Takehara K; Kamiura S; Tsuda N; Takei Y; Shigeta S; Matsumura N; Yoshida H; Motohara T; Watari H; Nakamura K; Ueda A; Tasaka N; Ishikawa M; Hirashima Y; Kudaka W; Taguchi A; Iwata T; Takahashi F; Kukimoto I; Yoshikawa H; Yaegashi N; Matsumoto K;
    Cancer Sci; 2022 Apr; 113(4):1428-1434. PubMed ID: 35043515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.
    Saeki Y; Saito M; Irie T; Itoh F; Enatsu A; Komura H; Fujii M; Fujii R; Hidaka N; Maehama T; Shirasu N; Waseda T; Shibata T; Takada E; Mibe K; Sakamoto J; Yamada S; Takakura M; Sasagawa T
    J Med Virol; 2024 Feb; 96(2):e29413. PubMed ID: 38314927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical cancer risk perceptions, sexual risk behaviors and sexually transmitted infections among Bivalent Human Papillomavirus vaccinated and non-vaccinated young women in Uganda - 5 year follow up study.
    Kumakech E; Andersson S; Wabinga H; Musubika C; Kirimunda S; Berggren V
    BMC Womens Health; 2017 Jun; 17(1):40. PubMed ID: 28576143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus vaccination and cervical cytology in young minority women.
    Brogly SB; Perkins RB; Zepf D; Longtine J; Yang S
    Sex Transm Dis; 2014 Aug; 41(8):511-4. PubMed ID: 25013981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.
    Hu SY; Kreimer AR; Porras C; Guillén D; Alfaro M; Darragh TM; Stoler MH; Villegas LF; Ocampo R; Rodriguez AC; Schiffman M; Tsang SH; Lowy DR; Schiller JT; Schussler J; Quint W; Gail MH; Sampson JN; Hildesheim A; Herrero R;
    J Natl Cancer Inst; 2022 Sep; 114(9):1253-1261. PubMed ID: 35640980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
    Kudo R; Yamaguchi M; Sekine M; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
    J Infect Dis; 2019 Jan; 219(3):382-390. PubMed ID: 30299519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands.
    Schurink-van 't Klooster TM; Siebers AG; Hoes J; van Kemenade FJ; Berkhof J; Bogaards JA; de Melker HE
    Cancer Med; 2023 May; 12(10):11786-11794. PubMed ID: 36965085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women.
    Shiko Y; Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
    BMC Infect Dis; 2020 Nov; 20(1):808. PubMed ID: 33153446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
    Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
    J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection.
    Li C; Hall TG; Hall JJ; He WQ
    Epidemiol Infect; 2023 Feb; 151():e37. PubMed ID: 36789960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
    Lee GY; Inthasorn P; Laowahutanont P; Lawpoolsri S; Kamolratanakul S; Lungchukiet P; Oh J; Termrungruanglert W; Taechakraichana N; Pitisuttithum P
    Vaccine; 2022 Mar; 40(13):1968-1976. PubMed ID: 35190207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of Human Papillomavirus Vaccination and Association with HPV-16 and HPV-18 DNA Detection in Young Women.
    Feder MA; Kulasingam SL; Kiviat NB; Mao C; Nelson EJ; Winer RL; Whitham HK; Lin J; Hawes SE
    J Womens Health (Larchmt); 2019 Oct; 28(10):1428-1435. PubMed ID: 31264912
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
    Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
    Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
    BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of HPV vaccination in women reaching screening age in Italy.
    Carozzi FM; Ocello C; Burroni E; Faust H; Zappa M; Paci E; Iossa A; Bonanni P; Confortini M; Sani C
    J Clin Virol; 2016 Nov; 84():74-81. PubMed ID: 27728850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.